Net sales remained at zero, with losses deepening year-over-year. A recent share issue raised 3.13 million SEK, funding operations into next year but not covering all debt. Focus is on demonstrating the new Förevaporeringsenheten and securing further financing for clinical trials.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.